U.S. prescriptions for embattled cholesterol drugs Vytorin and Zetia dropped 13% in February from January levels, after the ENHANCE study raised questions about their effectiveness.
Schering-Plough, which has a joint venture with Merck to market the drugs, disclosed Monday that total prescriptions for February were 2.8 million, versus 3.2 million in January.
The 13% drop in prescriptions for Vytorin and Zetia in February was steeper than the 7% decline in the broader market for cholesterol drugs that was due largely to the shorter month. Total U.S. cholesterol drug prescriptions fell to 18.9 million in February from 20.4 million in January, Schering-Plough said, citing data from IMS Health.
More
No comments:
Post a Comment